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BACKGROUND & AIMS: Gastric cancer is the second leading cause of cancer death 
worldwide. Early diagnosis of the stage of mucosal cancer is one of the best strategies for 
improving survival. However, an accurate diagnosis of depressed gastric mucosal cancer is 
difficult using conventional white-light imaging (C-WLI) endoscopy. We aimed to compare 
the real-time diagnostic yield of C-WLI for small depressed gastric mucosal cancers with that 
of magnifying narrowband imaging (M-NBI). METHODS: We recruited a gastric-cancer-
enriched population for this multicenter, prospective, randomized controlled trial. Patients 
with newly detected, undiagnosed, depressed lesions 10 mm in diameter were randomly 
assigned in a 1:1 ratio to C-WLI or M-NBI immediately after detection. The C-WLI group 
underwent M-NBI after C-WLI. We compared the diagnostic accuracy, sensitivity, and 
specificity between C-WLI and M-NBI, and assessed the diagnostic yield of M-NBI 
conducted in conjunction with C-WLI. RESULTS: We screened 1353 patients using 
esophagogastroduodenoscopy. Of these, 362 with undiagnosed small depressed lesions were 
randomly assigned to M-NBI (n = 182) or C-WLI (n = 180); 353 were included in the 
analysis (n = 177 and 176, respectively). Forty gastric cancers (20 per group) were newly 
diagnosed. The diagnostic capabilities of M-NBI and C-WLI were (median): accuracy, 90.4% 
and 64.8%; sensitivity, 60.0% and 40.0%; and specificity, 94.3% and 67.9%, respectively. 
The accuracy and specificity of M-NBI were greater than those of C-WLI (P < .001); the 
difference in sensitivity was not significant (P = .34). M-NBI in conjunction with C-WLI 
significantly enhanced the performance of C-WLI alone: accuracy increased from (median) 
40.0%  to 95.0%, P < .001; sensitivity increased from 67.9% to 96.8%, P < .001; and 
specificity increased from 64.8% to 96.6%, P < .001. CONCLUSION: M-NBI might 
represent a new standard examination modality for diagnosing depressed small gastric 
mucosal cancers accurately (Clinical trial number, UMIN-CTR000001072). 
Keywords: Gastric cancer; Early detection; Accuracy; NBI.
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Gastric cancer is the fourth most common malignancy and the second leading cause of death 
from cancer worldwide.
1
 Early detection and curative treatment are the best strategies for 
improving patient survival. Esophagogastroduodenoscopy is the most sensitive method of 
early detection of gastric cancers. However, an accurate early diagnosis of gastric mucosal 
cancer is difficult with conventional white-light imaging (C-WLI) endoscopy; nevertheless, it 
remains the standard endoscopic examination modality worldwide. 
Detection of mucosal cancers 20 mm in diameter is ideal, as they are curable using 
minimally invasive treatments such as endoscopic mucosal resection (EMR) and endoscopic 
submucosal dissection (ESD).
2,3
 Among the gastric mucosal cancers, the depressed type is the 
predominant morphology.
4–6
 However, small depressed cancers (10 mm in diameter) are 
more difficult to distinguish from benign abnormalities (such as inflammation) compared 
with elevated cancers. Although chromoendoscopy using indigo carmine has contributed to 
an improvement in the diagnosis of gastric mucosal cancers,
7
 there is no evidence of the 
superiority of chromoendoscopy over C-WLI. Therefore, C-WLI endoscopy remains the 
standard imaging modality for diagnosing gastric mucosal cancers. 
Histological evaluation of biopsy specimens from suspicious lesions is conventionally 
used to confirm a diagnosis. A highly accurate diagnosis without the need for a biopsy is the 
ultimate goal of endoscopists, as this would decrease the number of unnecessary biopsies, 
especially when confirming a negative biopsy of any suspicious cancerous lesion. This could 
reduce the risk of postbiopsy bleeding, costs associated with the procedure, and the workload 
on pathologists. 
Magnifying narrowband imaging (M-NBI), a recently developed advanced endoscopic 
imaging technology, was reported to be useful for the accurate diagnosis of gastric 




 and intestinal metaplasia.
15
 However, no 
randomized trials have been conducted to compare M-NBI with C-WLI. The present study 
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was designed to assess and compare the real-time diagnostic yield of C-WLI for depressed 
gastric mucosal cancers with that of M-NBI when performed by skilled endoscopists. 
Methods 
Study Design and Participants 
This randomized, controlled, open-label, multicenter trial was conducted at nine centers 
in Japan. This study was conducted according to the Standards for the Reporting of 
Diagnostic Accuracy Studies (STARD) initiative
16
 and the Declaration of Helsinki. 
The frequency of synchronous or metachronous multiple gastric cancers was reported 
as 3–5 per 100 patient years,17–19 which is higher than the incidence of gastric cancer in the 
general population. In other words, patients with gastric cancer might constitute a cancer-
enriched population, which may be a more suitable model for screening of potential gastric 
cancers than the general population. Therefore, we recruited patients aged 20 years or older 
with untreated gastric cancers and patients with a history of gastric cancer. Patients who had 
been treated with EMR or ESD were included in the latter group, as their stomachs were 
preserved with minimum injury. We excluded patients who had been treated with surgical 
resection, as the stomach was either removed or was reduced in size. Other exclusion criteria 
were serious complications that could interfere with the examination protocol and the use of 
medication that might interfere with the collection of a biopsy specimen. Written informed 
consent was obtained, and the institutional review board of each participating hospital 
approved the study. The clinical trial number of this study was UMIN-CTR000001072. 
To detect a target lesion, screening was done using C-WLI endoscopy. Previously 
undetected lesions were considered ideal potential targets for evaluating the diagnostic yield 
without bias. Therefore, the target lesions for this study were “newly detected and 
undiagnosed” small depressed gastric lesions 10 mm in diameter. We did not target lesions 
7 
 
that had been analyzed histologically. Small depressed lesions with apparent erosion or 
ulceration were also not evaluated, as it is difficult to visualize surface changes in these 
lesions. If the patient had multiple such lesions, only the first lesion detected was selected for 
examination. The diameter of each lesion was estimated by comparing it with the size of the 
biopsy forceps. 
Randomization and Masking 
When a target small depressed lesion was detected by C-WLI screening, patients were 
immediately assigned randomly to undergo detailed examination using C-WLI or M-NBI at a 
1:1 ratio. After the randomization, all endoscopists knew which imaging method would be 
used for the detailed examination when making a diagnosis of the target lesion. 
Randomization was performed promptly on-site using tables of random numbers stratified by 
hospital, and the results thereof were kept in sealed, numbered envelopes. The random 
allocation sequence was prepared at the data management center. Both the assignment result 
and the corresponding envelope number were recorded by the data management center. At 
each participating hospital, sealed envelopes were stored by a third party who was not 
involved in the study, and the envelopes were opened by an assistant physician in serial order 
only when randomization was performed. The assigned patient identification number, 
envelope number, and the assignment result were recorded on-site and faxed to the data 
management center on the day of the examination. 
Procedure and Endpoints 
The study design and the protocol examination were outlined in the supplemental figure 
(Supplement 1). The diagnosis for the target lesion was made by one endoscopist according 
to predetermined diagnostic criteria for C-WLI and M-NBI without any consultation with 
other physicians, and an assistant physician immediately recorded the results using a case 
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report form. For each modality, the interval between the start of the observation and the time 
at which an endoscopic diagnosis was made was measured using a stopwatch. For the C-WLI 
group, M-NBI examination was performed after completion of a diagnosis based on C-WLI. 
This procedure was used to evaluate the effect of using M-NBI in conjunction with C-WLI. 
After all records were compiled, at least one biopsy specimen was obtained from the target 
lesion. 
The primary aim of the study was to compare the diagnostic accuracy between C-WLI 
and M-NBI. The secondary aim was to compare diagnostic sensitivity, specificity, and 
examination time between C-WLI and M-NBI, and to evaluate the effects of an additional M-
NBI study after the initial C-WLI in terms of diagnostic accuracy, sensitivity, specificity, and 
examination time. Histopathology diagnosis of obtained biopsy specimens was used as a gold 
standard for the diagnosis. 
Endoscopy System 
The NBI system is an innovative optical-image-enhanced technology that involves a 
narrow bandwidth NBI filter and is mounted in the video endoscopy system. The central 
wavelengths of the NBI filters are 415 nm and 540 nm, and each has a bandwidth of 30 nm. 
As 415 nm and 540 nm light are well absorbed by hemoglobin, the microvascular 




We used high-resolution magnifying endoscopy with a capability of 80-fold optical 
magnification (GIF-Q240Z, GIF-H260Z, and GIF-FQ260Z; Olympus Medical Systems, 
Tokyo, Japan) and a high-resolution liquid-crystal monitor (OEV191H; Olympus Medical 
Systems). We alternated between the two imaging modalities (C-WLI and M-NBI) by 
pushing a button on the endoscope (EVIS LUCERA SPECTRUM system, Olympus Medical 
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Systems). We used a fixed-structure-enhancement setting and color tone for the video 
processor. 
Participating Endoscopists 
All examinations were performed by 31 endoscopic specialists accredited by the Japan 
Gastroenterological Endoscopy Society in nine institutes. Before the onset of the study, all 
participating endoscopists were trained using images of small depressed lesions to minimize 
diagnostic variation between them. 
Diagnostic Criteria for C-WLI and M-NBI 
Figure 1 shows a representative endoscopic image of a small depressed gastric cancer 
and a small depressed benign lesion. The endoscopic diagnostic criteria for small depressed 
gastric cancers using C-WLI were defined based on previous reports of C-WLI findings: an 
irregular margin (IM) and a spiny, depressed area (SDA).
23
 The observation of two findings 
(IM and SDA) in the target lesion was classified according to three categories: present, absent, 
or indeterminate. 
The endoscopic diagnostic criteria for small depressed gastric cancers using M-NBI 
were defined based on previous reports by Yao et al.: a demarcation line (DL) between the 
depressed cancerous lesion and the surrounding noncancerous area and an irregular 
microvascular pattern (IMVP) inside the lesion.
24
 Observations of two findings (DL and 
IMVP) in the target lesion were also classified according to three categories: present, absent, 
or indeterminate. 
Endoscopic diagnoses were determined according to the combined visibility of the two 
findings as follows (Supplement 2). 
(1) If both findings were present, the diagnosis was “cancer.” 
(2) If either finding was indeterminate, the diagnosis was “inconclusive.” 
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(3) If either or both findings were absent, the diagnosis was “noncancerous.” 
For analyzing diagnostic accuracy, sensitivity, and specificity, lesions diagnosed as 
“inconclusive” were considered as endoscopic “noncancerous” lesions. 
Pathology Diagnosis 
The biopsy specimens were evaluated using hematoxylin–eosin staining. The 
diagnostic pathology criteria were based on the revised Vienna classification.
25
 C4 (mucosal 
high-grade neoplasia) or C5 (submucosal invasion by neoplasia) were diagnosed as cancer, 
and C1 (negative for neoplasia), C2 (indefinite for neoplasia), or C3 (mucosal low-grade 
neoplasia) were diagnosed as noncancerous lesions. In this study, we used a central system of 
consultation with a main expert pathologist. If an indeterminate lesion were to be encountered, 
it was scheduled to be reviewed by this consulting pathologist in making a final diagnosis. 
Statistical Analysis 
We assumed that the accuracy, sensitivity, and specificity of C-WLI and M-NBI 
compared with histological diagnosis would be 60% and 85%, respectively. To set a 
probability for error of 0.05 and attain a power of 80% for testing the superiority of M-NBI, 
108 patients including at least 43 cancerous lesions were needed. Next, we calculated how 
many patients would need to be screened. As the frequency of small depressed lesions was 
reported to be 8.1% in the general population,
9
 the required size of the screening sample was 
1100 patients. 
Statistical analysis was performed using SPSS software, version 17 (SPSS Inc., 
Chicago, IL, USA). Diagnostic performance: accuracy, sensitivity, specificity, positive 
predictive value (PPV), and negative predictive value (NPV) are presented as percentages 
with 95% confidence intervals (CIs). Continuous variables are expressed as medians and 
interquartile ranges (IQRs). Analyses of the difference in diagnostic performance between C-
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WLI and M-NBI were conducted using the population whose diagnoses had been confirmed 
by pathology using Pearson’s Chi-squared test. Analyses of the effect of additional M-NBI 
after the initial C-WLI on diagnostic performance were conducted using the population 
whose diagnoses had been confirmed by pathology and McNemar testing. Analysis of the 
examination duration was conducted using the population who completed protocol 
examination and the Mann–Whitney nonparametric test for comparisons between C-WLI and 
M-NBI, and the Wilcoxon signed-rank test for comparisons between C-WLI and C-WLI + 
M-NBI. All probability values calculated in this analysis were 2-sided, and P < .05 was 
considered significant. 
Results 
Between June 2008 and May 2010, 1365 patients were enrolled in the study. Eight 
patients refused to participate and 4 were registered twice; therefore, the remaining 1353 
patients were registered correctly and underwent endoscopic screening. Screening was 
discontinued for 2 patients because of a large amount of residual digesta in the stomach and a 
severe vomiting reflex. Endoscopic screening was completed for the remaining 1351 patients. 
Of the screened patients, 362 (26.8%) had newly detected, undiagnosed small 
depressed lesions and were randomly assigned to one of two groups: (1) 180 patients were 
examined using C-WLI, followed by M-NBI; (2) 182 patients were examined using M-NBI 
alone. Four patients in the C-WLI group (1 patient’s lesion was >10 mm in diameter, 1 was 
discontinued from the examination because of MalloryWeiss syndrome, and 2 had a missed 
biopsy) and 5 patients in the M-NBI group (1 was examined with an unpermitted endoscope 
and 4 missed biopsy) were excluded. Data for 176 patients of the C-WLI group and 177 
patients of the M-NBI group were used for the final analysis (Figure 2). The demographic 
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and lesion characteristics of the 2 groups were balanced. In both groups, 13% of patients had 
newly diagnosed gastric cancer (20 per group; Table 1). 
Table 2 shows endoscopic diagnoses for all lesions. Inconclusive diagnoses were 
obtained for 3 lesions (1.7%) using M-NBI, for 6 lesions (3.4%) using C-WLI, and for 2 
lesions (1.3%) using C-WLI followed by M-NBI. These lesions were considered endoscopic 
“noncancerous” lesions for analysis. 
The real-time diagnostic accuracy of M-NBI was significantly greater than that of C-
WLI (90.4% [95% CI, 85.1–94.3%] and 64.8% [95% CI, 57.2–71.8%], respectively; P 
< .001; Table 3). Real-time M-NBI diagnosis had greater specificity than C-WLI diagnosis 
(94.3% [95% CI, 89.4–97.3%] and 67.9% [95% CI, 60.0–75.2%], respectively; P < .001; 
Table 3). The diagnostic sensitivities of M-NBI and C-WLI did not differ significantly 
(60.0% [95% CI, 36.1–80.9%] and 40.0% [95% CI, 19.1–63.9%], respectively; P = .34; Table 
3). M-NBI in conjunction with C-WLI significantly enhanced the diagnostic performance of 
the latter: accuracy increased from 67.9% (95% CI, 60.0–75.2%) to 96.8% (92.7–99.0%; P 
< .001); sensitivity increased from 40.0% (95% CI, 19.1–63.9%) to 95.0% (75.1–99.9%; P 
< .001); and specificity increased from 64.8% (95% CI, 57.2–71.8%) to 96.6% (95% CI, 
93.5–99.1%; P < .001; Table 3). 
The median durations of the C-WLI and M-NBI procedures were 21 s (IQR, 12–40 s) 
and 55 s (IQR, 23–97 s), respectively, and this difference was highly significant (P < .001). 
The median total duration of C-WLI followed by M-NBI (72 s [IQR, 40–144 s]) was 
significantly longer than that of C-WLI alone (P < .001). All patients tolerated the procedures 
well (Table 3). 
Figure 3 shows the PPV and NPV data for each examination. M-NBI significantly 
improved the PPV compared with C-WLI alone to 57.1% (95% CI, 36.0–78.3%) from 13.8% 
(95% CI, 2.9–22.7%; P = .001). Furthermore, C-WLI followed by M-NBI dramatically 
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improved the PPV from 13.8% (95% CI, 2.9–22.7%) to 79.2% (95% CI, 62.9–95.4; P < .001). 
Similarly, the NPV of C-WLI of 89.8% (95% CI, 84.4–95.3) was improved by M-NBI to 
94.9% (95% CI, 91.4–98.3; P = .16) and by C-WLI followed by M-NBI to 99.3% (95% CI, 
98.1–100; P < .001). 
Detailed C-WLI examination was discontinued during the procedure in 1 patient 
(1/362; 0.3%) because of bleeding associated with Mallory–Weiss syndrome. Although the 
bleeding stopped spontaneously without any endoscopic hemostatic treatment, a biopsy 
specimen was not obtained because the suspicious target lesion was missed. Two patients 
(2/362; 0.6%) were hospitalized on the day after examination because of bleeding from the 
biopsy site; although 1 patient needed a blood transfusion, both patients were discharged 
within a few days. None of the 3 patients experienced prolonged adverse effects. There were 
no serious adverse events directly related to the endoscopic observations. 
Table 4 summarizes the clinical courses and pathological diagnoses of 40 gastric 
cancers in 40 patients. Thirty-two patients were treated endoscopically (by EMR or ESD). 
Five patients underwent surgical resection for synchronous advanced gastric cancers. The 
remaining 3 patients did not receive any treatment; 2 had other concomitant noncurable 
malignancies, and 1 refused treatment. Histologically, 39 lesions were of the intestinal type 
and one lesion was of the diffuse type. Regarding the depth of the 37 lesions that were 
removed, 35 were mucosal cancers, 2 of which were accompanied by submucosal invasion 
(0.3 mm and 0.8 mm). The depths of the 3 untreated lesions were estimated endoscopically as 
2 mucosal cancers and 1 submucosal cancer. 
Discussion 
In this multicenter, randomized trial, we compared the diagnostic yield of C-WLI with 
that of M-NBI for small gastric cancers. The primary aim of this study was to compare 
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directly the real-time diagnostic accuracy of two randomly assigned endoscopic modalities. 
One was the worldwide standard method of C-WLI; the other was M-NBI, which is the most 
advanced imaging method at present. This endpoint is the most important aspect of this study, 
because if C-WLI proves superior to M-NBI, such advanced methods are not needed in 
practice. However, if M-NBI is indeed better than C-WLI, it should be used more in daily 
practice. The secondary aim of this study was to evaluate the additional effect of performing 
M-NBI after C-WLI. This endpoint is also important, because in daily practice M-NBI are 
usually performed after carrying out C-WLI. Therefore, the results might reflect the practical 
diagnostic potential. To evaluate these aims, we used a strictly controlled randomized study. 
Furthermore, the endoscopic diagnosis in each method (C-WLI and M-NBI) was made on-
site and independently to avoid any bias. 
M-NBI, especially when used in conjunction with C-WLI, significantly enhanced real-
time sensitivity, specificity, and accuracy of diagnosis, therefore, we concluded that M-NBI is 
essential modality for diagnosing small gastric mucosal cancer. Although there are reports on 
the diagnostic yield of M-NBI for differential diagnosis of gastric lesions, some were 
performed at only one institute,
9,10,12,13
 one was evaluated by several expert endoscopists 
using stored images and did not involve real-time assessment,
12
 and one included gastric 
lesions with a definite diagnosis.
13
 To overcome these limitations, our study targeted newly 
detected and undiagnosed gastric superficial lesions, which were evaluated on-site. For these 
reasons, the present results are the most reliable and could be a milestone in the field of 
endoscopic diagnosis of early gastric cancers. 
Regarding accuracy and specificity, M-NBI alone yielded excellent results (90.4% and 
94.3%, respectively), which were significantly better than those obtained with C-WLI. 
However, the sensitivities of M-NBI alone (60.0%) and C-WLI alone (40.0%) were lower 
than the estimated values: 85% for M-NBI and 60% for C-WLI. The low sensitivity of C-
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WLI might be acceptable considering the difficulty of diagnosing small gastric cancers in 
daily clinical practice. Although the reason for the low sensitivity of the M-NBI group is 
unknown, it might be associated with the examination protocol in this study; M-NBI 
observation was performed without evaluating a gross finding of lesions using C-WLI. In 
daily practice, magnifying examinations are usually performed after C-WLI. Actually, when 
performed after the C-WLI observation, M-NBI yielded excellent diagnostic performance in 
terms of accuracy, sensitivity, and specificity (all values were >95%). In addition, M-NBI and 
C-WLI followed by M-NBI significantly improved the PPV and NPV compared with C-WLI 
alone. This has enormous significance in clinical practice, because the examination with high 
PPV and high NPV might enable the clinician to make appropriate judgments as to which 
lesion needs pathology to confirm the diagnosis. When the lesion is suspected to be a 
neoplasm by C-WLI followed by M-NBI, taking a biopsy is highly recommended to confirm 
the pathology. On the other hand, when the lesion is not suspected to be a neoplasm by M-
NBI alone or by C-WLI followed by M-NBI, we could avoid a negative biopsy. These results 
have the potential to enable so-called “optic biopsy”. Taken together, C-WLI followed by M-
NBI might be the best approach for making accurate diagnoses of small gastric cancers. 
The durations of the M-NBI and C-WLI followed by M-NBI examinations were 34 s 
and 51 s, respectively, significantly longer than that required for C-WLI alone. However, 
these durations are clinically acceptable, as we managed to make accurate diagnoses without 
having to insert a spraying catheter or use indigo carmine. The importance of simple methods 
and accurate diagnoses for clinical practice is indisputable. Thus, Li et al. showed that 
confocal laser endomicroscopy can be used to identify gastric superficial cancers with high 
validity and reliability.
26
 However, confocal laser endomicroscopy requires the intravenous 
administration of a contrast agent. In contrast, M-NBI can be utilized by simply pushing a 
button on the endoscope. In addition, evaluation of DLs and IMVPs is sufficient for diagnosis 
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with M-NBI, whereas confocal laser endomicroscopy requires knowledge of histopathology 
procedures for diagnosis. 
Major bleeding caused by an endoscopic biopsy is rarely reported.
27
 However, in our 
study, 2 patients experienced bleeding from the biopsy site. The best way of avoiding such 
bleeding is to avoid unnecessary biopsies. M-NBI, especially when used in conjunction with 
C-WLI, could help to reduce the number of unnecessary biopsies. 
Our study has some limitations. First, the number of cancerous lesions was small, and it 
was less than the required sample size. This might be associated with insufficient power to 
evaluate sensitivity adequately. Then, further large numbers of patients for screening are 
needed to evaluate the sensitivity for diagnosing small gastric mucosal cancers of each 
modality. Second, this study was open-labeled because the endoscopists knew which imaging 
modality was in use. Thus, a blinded study was impossible. Third, there is no arm which 
includes dye-based imaging method such as indigocarmine or acetic acid. Indigo carmine and 
acetic acid are useful, but these dyes are only used in a few countries and institutes, and then, 
the standard worldwide endoscopic method to diagnose early gastric cancer is still C-WLI 
without any dye use. In addition, if we used a chromoendoscopy arm in this study, the 
required sample size would need to be enlarged and the study design and statistical analyses 
would be excessively complex. For these reasons, we did not include the dye-based imaging 
method. 
Early detection of small gastric cancers makes it possible to effect a cure using 
minimally invasive treatments such as EMR and ESD. In this study, all of the newly 
diagnosed small gastric cancers were good candidates for these procedures. Among the 37 
cancers removed, 35 (95%) were mucosal. Early diagnosis using M-NBI and minimally 
invasive treatment is ideal for patients with gastric cancers, as it will improve their survival 
and quality of life. Although eradication of Helicobacter pylori is effective in reducing the 
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incidence of gastric cancer,
17,28
 endoscopic examination using M-NBI in conjunction with C-
WLI should be indicated for high-incidence areas such as East Asia, South America, Eastern 
European countries, and Russia.
29
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Figure 1. Representative endoscopic findings for gastric small depressed lesions. 
Panels A–C show cancers and panels D–F show noncancerous lesions. Panel A shows an 
endoscopic image obtained using conventional white-light imaging (C-WLI). A small 
depressed lesion (arrowheads) is evident in the anterior wall of the lower part of the gastric 
body. This lesion was evaluated as having an irregular margin (IM) and a spiny depressed 
area (SDA). Panel B shows an endoscopic image obtained using magnifying narrowband 
imaging (M-NBI), which enabled clear visualization of the demarcation line (DL) and an 
irregular microvascular pattern (IMVP). Panels A and B are schematic representations of 
the images shown in panels A and B, respectively. Panel C shows a lesion that was 
histologically diagnosed as a differentiated adenocarcinoma, Vienna Classification C4. Panel 
D shows an image obtained using C-WLI. A small reddish area (arrowheads) is evident in 
the anterior wall of the upper part of the gastric body. Because the depressed area was not 
“spiny” and because a definite margin was not apparent, this case was evaluated as not 
having an SDA or an IM. Panel E shows an image obtained using M-NBI, which enabled 
clear visualization of a DL and the absence of an IMVP. Panels D and E are schematic 
representations of the images shown in panels D and E, respectively. Panel F shows a 
lesion that was histologically diagnosed as gastritis, Vienna Classification C1. 
 
Figure 2. Patient enrollment, randomization, and examination. 
 
Figure 3. Positive predictive value (PPV) and negative predictive value (NPV) in each 
examination. 
*The PPV for M-NBI was significantly higher than for C-WLI (P = .001). The NPV in M-NBI 
was higher than that of C-WLI; however, the difference was not significant (P = .16). **Both 
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PPV and NPV were significantly enhanced by additional examination using M-NBI compared 
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(n = 176) 
M-NBI 
(n = 177) 
P  
Age (years) Median (range) 69 (45–93) 69 (37–87) .56 
Gender Male 138 140 
.79 
Female 38 37 
Endoscope GIF-Q240Z 71 65 
.83 GIF-H260Z 104 109 
GIF-FQ260Z 1 3 
Size of lesion 
(mm) 
5 74 71 
.75 
>5 102 106 
Mean 5.6 5.6 .97 
Location of 
lesion 
U ant. 4 2 
.51 
les. 9 10 
post. 22 12 
gre. 4 3 
M ant. 7 7 
les. 13 25 
post. 12 11 
gre. 8 6 
L ant. 18 23 
les. 25 33 
post. 26 18 
gre. 28 27 
Histopathology 
diagnosis 
Cancer 20 20 
1.00 
Noncancerous 156 157 
M-NBI, magnifying narrowband imaging; C-WLI, conventional white-light imaging; U, 
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upper third; M, middle third; L, lower third; ant., anterior wall; les., lesser curvature; 




Table 2. Endoscopic Diagnoses for All Small Depressed Lesions 
Group Method 























































Table 3. Diagnostic Performance of C-WLI and M-NBI for Gastric Small Depressed 
Lesions 
Group Method 
Accuracy Sensitivity Specificity 
Exam. time 
(s) 
(95% CI) (95% CI) (95% CI) 
Median 
(IQR) 


























*P < .001 for M-NBI vs C-WLI; **P < .001 for C-WLI vs C-WLI + M-NBI 
M-NBI, magnifying narrowband imaging; C-WLI, conventional white-light imaging; 




Table 4. Clinical Course and Pathological Diagnosis of Patients With 
Gastric Cancers 
No. of patients  40 
Treatment EMR/ESD 2/30 
Surgery 5 
No treatment 3 
Histological type Adenocarcinoma 40 
(intestinal type) (39) 
(diffuse type) (1) 
Other diagnosis 0 
Pathological depth m 35 
sm 2 
mp  0 
Unknown 3 
EMR5, endoscopic mucosal resection; ESD, endoscopic 
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3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons No change 
Participants 4a Eligibility criteria for participants #6-7 
4b Settings and locations where the data were collected #9 
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Study flow 
Written informed consent was obtained from all eligible patients. To detect a target 
lesion, endoscopic screening was done using conventional white-light imaging (C-WLI). 
If no target lesion was detected, routine endoscopic examination were performed 
without study entry. When a target lesion was detected, patients were immediately 
assigned randomly to undergo detailed examination using C-WLI or magnifying 
narrowband imaging (M-NBI). For the C-WLI group, M-NBI examination was 
performed after completion of a diagnosis based on C-WLI. After all diagnoses were 
compiled, at least one biopsy specimen was obtained from the target lesion. The primary 
aim of this study was to compare directly the real-time diagnostic accuracy of two 
randomly assigned endoscopic modalities; C-WLI and M-NBI (solid line box). The 
secondary aim of this study was to evaluate the additional effect of performing M-NBI 
after C-WLI (dash line box). 
 
Diagnostic method based on endoscopic findings 
Endoscopic diagnoses were made according to the combination of the endoscopic 
findings. In the case of conventional white-light imaging (C-WLI), an irregular margin 
and a spiny depressed area were used for the diagnostic findings. In the case of 
magnifying narrowband imaging (M-NBI), a demarcation line between the depressed 
cancerous lesion and the surrounding noncancerous area and an irregular 
microvascular pattern inside the lesion were used for the diagnosis. If both findings 
were present in each examination, the diagnosis of “cancer” was made. If either finding 
was indeterminate, the diagnosis was “inconclusive.” If either or both findings were 
absent, the diagnosis was “noncancerous”. 
 
 
Supplementary figure1: Study flow 
 
 
Supplementary figure 2: Diagnostic method based on endoscopic findings 
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